Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
18.09.2026 13:23
AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
18.09.2026 13:05
JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
Lilly’s Newest Bull Says Near 300% Rally Is Only the Beginning
18.09.2026 12:30
Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.
Eli Lilly (NYSE:LLY) Fits a Dividend Quality Screen Despite Its Low Yield
18.09.2026 11:40
Eli Lilly scores 7/10 on dividends with 15.17% growth, strong profitability, and low payout, though its 0.75% yield and high P/E are key trade-offs.
AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell Agreements
18.09.2026 10:50
STOCKHOLM, SE / ACCESS Newswire / September 18, 2026 / AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that an updated company presentation in English is now available. In the presentation, CEO Martin Jönsson provides an updated view of the company following the recently signed collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based Quan
What Does Eli Lilly (LLY) Gain From Its New Genetic Medicine Partnership?
18.09.2026 10:10
Eli Lilly (NYSE:LLY) has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases. The agreement centers on QurCan's polymer lipid nanoparticle delivery platform for central and peripheral nervous system targets, with Eli Lilly responsible for later development and commercialization. Lilly is also making a strategic investment in QurCan Therapeutics, tying capital directly to progress in genetic medicine delivery...
Veradermics: Buy Before The Catalysts
18.09.2026 09:39
Veradermics (MANE) stock outlook: Phase 3 VDPHL01 readouts, FDA approval odds, cash runway, and hair loss market upsideâsee the bull case and act now.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
18.09.2026 09:22
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $1284
18.09.2026 08:28
Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1273 to $1284.
1 Safe-and-Steady Stock Worth Your Attention and 2 We Question
18.09.2026 07:37
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
This Trend is Excellent News for Eli Lilly and Its Investors
17.09.2026 08:35
Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
16.09.2026 16:20
The company is still looking to bounce back after the beating it took in recent years.
Novo Nordisk: Why This Corporate Rebrand Is More Than Simply PR Posturing
16.09.2026 15:33
Novo Nordisk A/S rebrands as âNovoâ to boost consumer focus and agility as GLP-1 competition and pricing pressures grow. Click for this NVO stock update.
Billionaire Ray Dalio’s Bridgewater’s and Cathie Wood’s ARK Portfolios: 2 Stocks They Both Own
16.09.2026 14:24
Billionaire Ray Dalio’s Bridgewater Associates and Cathie Wood’s ARK Invest follow sharply different investment philosophies. Bridgewater generally runs a diversified, macro-driven portfolio that balances exposure across assets, countries and economic environments. ARK concentrates on companies it believes can benefit from disruptive innovation. Still, Insider Monkey’s analysis of their second-quarter 13F filings shows that the two […]
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
16.09.2026 13:52
BOSTON, September 16, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data.
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday
16.09.2026 13:17
Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Se
Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know
16.09.2026 13:05
Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
16.09.2026 13:00
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly (LLY) Stock Could Be A Bargain At This Price
16.09.2026 12:13
Eli Lilly has turned into one of the market’s biggest healthcare stories, with the share price at US$1,136.11 and a very large 5 year gain, so the obvious question for you is whether that move is backed up by the cash the business can generate. With so much of the current debate driven by excitement around obesity and diabetes treatments, the price now invites a closer look at what those therapies may mean for long term cash flows. The stock is up about 416.5% over 5 years, which puts a lot...
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
16.09.2026 12:00
SOUTH SAN FRANCISCO, Calif., September 16, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model.